Results 141 to 150 of about 19,024 (248)

Long‐term efficacy of biologics in moderate‐to‐severe hidradenitis suppurativa: A systematic review and MAIC

Journal of the European Academy of Dermatology and Venereology, EarlyView.
A matching‐adjusted indirect treatment comparison (MAIC) was conducted, comparing approved biologics for long‐term (48–52 weeks) treatment of moderate‐to‐severe hidradenitis suppurativa (HS). Using weighted patient‐level trial data allowed re‐estimation of relative bimekizumab efficacy compared with aggregate secukinumab and adalimumab trial data ...
Thrasyvoulos Tzellos, Vincent Piguet, Michael Frank Mørup, Leah Davis, Vanessa Taieb, Sandeep Kiri, Victoria Shodimu, Abby Paine, Brian Kirby, Haley B. Naik   +9 more
wiley   +1 more source

Genomic and proteomic insights into hidradenitis suppurativa

Journal of the European Academy of Dermatology and Venereology, EarlyView.
A dual pathogenic model of HS involving both epithelial dysfunction and systemic inflammation is supported. The HLA‐DRA association hints at autoimmune overlap, but the proteomic signature which is dominated by innate immune mediators favours an autoinflammatory classification, which may guide future therapeutic strategies and patient stratification ...
Maria Argyropoulou, Emmanouil Stylianakis, Isis Ricaño‐Ponce, Nick Keur, Theodora Kanni, Dimitra Stergianou, Mihai G. Netea, Vinod Kumar, Evangelos J. Giamarellos‐Bourboulis   +8 more
wiley   +1 more source

Darier disease—A review highlighting new insights from the Darier Disease International Task Force

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review provides a global, clinically focused overview of DD, detailing cutaneous and extracutaneous manifestations, disease classification and severity scoring. It emphasizes early recognition, multidisciplinary management and practical guidance for dermatologists to apply evidence‐based care in diverse skin phototypes. Abstract Darier disease (DD)
Sofia Labbouz, Alain Hovnanian, Grace Xiong, Dedee Frances Murrell, Simon M. Mueller, Khaled Ezzedine, Nessa Aghazadeh Mohandesi, Ahmed Salem Aldhaheri, Nissim Asayag, Eulalia Baselga, Chen Nadler, Keith Choate, Chia‐Yu Chu, John Robert Edminister, Emmanuella Guenova, Melis Gönülal, Antoni Gostynski, Ankan Gupta, Lalit Kumar Gupta, Juliette Mazereeuw‐Hautier, Wolfram Hoetzenecker, Peter Itin, Marek Jankowski, Akiharu Kubo, Haur Yueh Lee, Julia Scott Lehman, Anfisa Lepekhova, Márta Medvecz, Jemima E. Mellerio, Verena Moosbrugger‐Martinz, Amy S. Paller, Dóra Plázár, Amadeu José Rodrigues Queiróz, Josep Riera‐Monroig, Ralph Rosa, Matthias Schmuth, Maella Severino Freire, Itzhak Shabat, Jonathan Shapiro, Cory L. Simpson, Diego Soto‐García, Alexander J. Stratigos, Gianluca Abel Tadini, Takuya Takeichi, Kaushal K. Verma, Jakob D. Wikström, Alexander Zink, Michael Ziv, Alexander Navarini, Roni Pircha Dodiuk‐Gad   +49 more
wiley   +1 more source

Cumulative isotretinoin dosing, treatment response and acne relapse: A randomized controlled trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this randomized controlled trial, cumulative isotretinoin doses of 120 and 150 mg/kg showed similar relapse rates at 12 months. Both regimens achieved substantial and comparable reductions in inflammatory acne lesions across the face, chest and back.
Ruggero Cascio Ingurgio, Angela Alfano, Antonio Costanzo, Julie S. Cronk, Rebecca Cummins, Benjamin S. Daniel, Ben J. Koszegi, Linda K. Martin, Clarisse G. Mendoza, Mae Ramirez‐Quizon, Lesley M. Rhodes, Heather I. Rishel, Adam I. Rubin, Fanny Satgé, Supriya Venugopal, Anna Wilson, Dedee F. Murrell   +16 more
wiley   +1 more source

The worldwide burden of skin diseases: Lessons from the Global Burden of Disease data

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Skin diseases are a major public health concern worldwide, causing significant personal, economic and social burdens. The Global Burden of Disease (GBD) initiative provides valuable insights but underestimates the burden of skin diseases, emphasizing the urgent need for improved data collection and global collaboration among stakeholders.
Luigi Naldi, Simone Cazzaniga, Carsten Flohr, Marco May Lee, Claire Fuller, Roderick Hay, Esther E. Freeman, Rashmi Sarkar, Ricardo Romiti, Antonio Torrelo, Qianjin Lu, Ncoza Dlova, Visnja Zaborski Breton, Jennifer Austin, Matthias Augustin, Henry Lim, Luca Borradori   +16 more
wiley   +1 more source

Addiction in chronic inflammatory skin diseases: A systematic review of prevalence, impact and screening practices

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This systematic review included 38 studies assessing substance‐related and behavioural addictions in patients with chronic inflammatory skin diseases. Nicotine and alcohol use were the most frequently reported addictive behaviours. Addictions were associated with increased disease severity, impaired treatment outcomes and greater psychosocial burden ...
Enya Müller, Stefanie Ziehfreund, Magdalena Saak, Sofia Besi, Kilian Eyerich, Alexander Zink   +5 more
wiley   +1 more source

Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Anumigilimab, a novel anti‐G‐CSF receptor antibody, was investigated in a phase 1b trial involving 39 patients with hidradenitis suppurativa or palmoplantar pustulosis. No serious safety concerns related to anumigilimab were noted, and PK and PD were dose dependent.
Johannes S. Kern, Simon Francis Thomsen, Georgios Kokolakis, Maurizio Podda, Gregor B. E. Jemec, Kurt Gebauer, Claus Zachariae, John Frew, Pablo Fernandez‐Peñas, Falk G. Bechara, Stefan Beissert, Sourabh Malandkar, Karen Scalzo‐Inguanti, Partha Nandy, Selvakumar Sukumar   +14 more
wiley   +1 more source

Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In adults with moderate AD post‐TCS and ‐TCI, who may otherwise be eligible for systemic therapy, 1.5% ruxolitinib cream improved clinical signs and symptoms in the TRuE‐AD4 study. Abstract Background In patients with moderate atopic dermatitis (AD), topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) often do not sufficiently ...
José Manuel Carrascosa, Vimal H. Prajapati, H. Chih‐ho Hong, Viktoria Eleftheriadou, Athanasios Tsianakas, Alexander A. Navarini, Ketty Peris, Eingun James Song, Raj Chovatiya, Sébastien Barbarot, Konstantin Popovic, Haq Nawaz, Qian Li, Vivek Purohit, Andreas Wollenberg   +14 more
wiley   +1 more source

The Prevalence and Characteristics of Adult Female Acne: A Cross-sectional Population-based Study

Acta Dermato-Venereologica
Anni Telkkälä, Jari Jokelainen, Terhi Piltonen, Laura Huilaja, Suvi-Päivikki Sinikumpu   +4 more
doaj   +1 more source

Dermatological Disease at a Tertiary Military Hospital in Burundi: A Retrospective Review

International Journal of Dermatology, EarlyView.
Doriane Sabushimike, Alison K. Wright, Marc Nimburanira, Patrick Budengeri, Christopher E. M. Griffiths, Darren M. Ashcroft   +5 more
wiley   +1 more source